Page 96 - Read Online

Page 421 Lv. J Transl Genet Genom 2021;5:414-22 https://dx.doi.org/10.20517/jtgg.2021.34

32. Lv DJ, Song XL, Huang B, et al. HMGB1 promotes prostate cancer development and metastasis by interacting with brahma-related
gene 1 and activating the Akt signaling pathway. Theranostics 2019;9:5166-82. DOI PubMed PMC
33. Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs
activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 2012;138:11-22. DOI PubMed
34. Jiang W, Wang Z, Li X, Fan X, Duan Y. High-mobility group box 1 is associated with clinicopathologic features in patients with
hepatocellular carcinoma. Pathol Oncol Res 2012;18:293-8. DOI PubMed
35. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and
poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010;136:677-84. DOI PubMed
36. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and
its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100. DOI PubMed
37. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is
associated with metastatic prostate cancer. Oncol Rep 2003;10:1863-8. PubMed
38. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated "danger signals" influence T-cell responses that promote the
progression of preneoplasia to cancer. Cancer Res 2013;73:629-39. DOI PubMed
39. Li T, Gui Y, Yuan T, et al. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
BJU Int 2012;110:E1125-30. DOI PubMed
40. Huang Z, Zhong Z, Zhang L, et al. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial
carcinoma cell lines via the NF-κB pathway. Sci Rep 2015;5:12807. DOI PubMed PMC
41. Kishi S, Nishiguchi Y, Honoki K, et al. Role of glycated high mobility group box-1 in gastric cancer. Int J Mol Sci 2021;22:5185.
DOI PubMed PMC
42. Li Y, He J, Zhong D, Li J, Liang H. High-mobility group box 1 protein activating nuclear factor-κB to upregulate vascular endothelial
growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer. J Int Med Res 2015;43:494-505.
DOI PubMed
43. Dhumale SS, Waghela BN, Pathak C. Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of
RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. IUBMB Life 2015;67:361-73. DOI PubMed
44. Su Z, Wang T, Zhu H, et al. HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive
feedback during nutrient depletion. Immunobiology 2015;220:539-44. DOI PubMed
45. Zhang Q, Liu S, Parajuli KR, et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.
Oncogene 2017;36:687-99. DOI PubMed PMC
46. Thapa D, Ghosh R. Chronic inflammatory mediators enhance prostate cancer development and progression. Biochem Pharmacol
2015;94:53-62. DOI PubMed
47. Simons BW, Durham NM, Bruno TC, et al. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates
prostate cancer progression. J Pathol 2015;235:478-89. DOI PubMed PMC
48. Sciarra A, Gentilucci A, Salciccia S, et al. Prognostic value of inflammation in prostate cancer progression and response to therapeutic:
a critical review. J Inflamm (Lond) 2016;13:35. DOI PubMed PMC
49. Kang R, Tang D, Schapiro NE, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating
mitochondrial bioenergetics. Oncogene 2014;33:567-77. DOI PubMed PMC
50. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by
HMGB1 and RAGE. Nat Immunol 2007;8:487-96. DOI PubMed
51. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal
motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002;62:4805-11. PubMed
52. Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1
(HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009;34:425-31. PubMed
53. Bao JM, He MY, Liu YW, et al. AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb
phosphorylation and degradation. Am J Cancer Res 2015;5:1741-50. PubMed PMC
54. Shetty AV, Thirugnanam S, Dakshinamoorthy G, et al. 18α-glycyrrhetinic acid targets prostate cancer cells by down-regulating
inflammation-related genes. Int J Oncol 2011;39:635-40. DOI PubMed
55. Liu J, Jiang G, Yang A, Yang G, Yang W, Fang Y. Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via
adjustment of androgen receptor phosphatization. Am J Transl Res 2016;8:4881-91. PubMed PMC
56. Patek S, Willder J, Heng J, et al. Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer
patients. Oncotarget 2017;8:4875-87. DOI PubMed PMC
57. Verrijdt G, Haelens A, Schoenmakers E, Rombauts W, Claessens F. Comparative analysis of the influence of the high-mobility group
box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid
receptors. Biochem J 2002;361:97-103. DOI PubMed PMC
58. Boonyaratanakornkit V, Melvin V, Prendergast P, et al. High-mobility group chromatin proteins 1 and 2 functionally interact with
steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol
1998;18:4471-87. DOI PubMed PMC
59. Henzler C, Li Y, Yang R, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in
prostate cancer. Nat Commun 2016;7:13668. DOI PubMed PMC
60. Reebye V, Frilling A, Habib NA, Mintz PJ. Intracellular adaptor molecules and AR signalling in the tumour microenvironment. Cell
Signal 2011;23:1017-21. DOI PubMed